Great microdialysis news in that news release and nice to see the updates on the xB3 programs and respective timelines in the Corporate Presentation.

xB3-001: Microdialysis measured changes in dopamine, serotonin and norepinephrine in response to xB3-001 are supportive of brain uptake and target engagement, and may serve as potential neuroactive biomarkers in future investivgations. These neurochemical changes are not to be considered as side effects, but instead as bioactive evidence of the drug getting past the blood brain barrier and into brain. Nothing on the NHP imaging studies in this latest presentation. Hopefully we hear something on this later in Q3 or in Q4. 

xB3-002: Proof of concept pre-clinical studies with Minerva Imaging for target engagement, distribution and efficacy look to be on schedule for Q3 2018, Q4 2018 and Q1 2019, respectively. 

xB3-007: Neurodegeneration program will be focusing on Gaucher's Disease to deliver the glucocerebrosidase (GCase) enzyme across the BBB. BiOasis will be performing pre-clinical proof of concept target engagement, distribution and pharmacokinetic/pharmacodynamic studies in Q3/Q4 2018. Both rodent and NHP models will be utilized.

xB3-008: Lysosomal Storage Disease program is still alive and focusing on Hunter's and Hurler's syndromes (MPS I and MPS II).

Exciting times ahead! 

BearDownAZ